Iressa™. Oncolytic, EGF receptor tyrosine kinase inhibitor

Drugs of the Future

Volumn 27, Issue 4, 2002, Pages 339-345

  Levin, Mark ^a   D'Souza, Nina ^a   Castaner J ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; GEMCITABINE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLOOD DISEASE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL CULTURE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG INFORMATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HEADACHE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LUNG NON SMALL CELL CANCER; NAUSEA; NORMAL HUMAN; PROSTATE CANCER; RASH; REVIEW; SOLID TUMOR;

EID: 0036284896     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.04.668736     Document Type: Review

References (43)

1. Studies leading to the identification of ZD 1839 (Iressa™): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
2. Cancer proteomics: From biomarker discovery to signal pathway profiling
3. Signaling - 2000 and beyond
4. Oncogenic kinase signalling
5. ATP competitive inhibitors of the EGF receptor tyrosine kinase: From research to the clinic
6. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anticancer therapy
7. Targeting growth factor receptors: Integration of novel therapeutics in the management of head and neck cancer
8. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members
9. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy
10. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
11. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors
12. Untangling the ErbB signalling network
13. Epidermal growth factor receptors: Critical mediators of multiple receptor pathways
14. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents
15. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases
16. Tyrosine kinase inhibitors-ZD1839 (Iressa)
17. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers
18. Continuous administration of ZD 1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability
19. Intermittent oral ZD 1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a phase I study
20. ZD 1839 "Iressa"
21. TGFα deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice
22. Strain-dependent epithelial defects in mice lacking the EGF receptor
23. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition
24. Activated extra-cellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments
25. Endocrine resistance in breast cancer can involve a switch towards EGFR signaling pathway and a gain of sensitivity to an EGFR-selective tyrosine kinase inhibitor, ZD1839
26. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation
27. Small molecule EGF receptor tyrosine inase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erb-2) overexpressing breast tumor cells
28. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2 overexpressing tumor cells
29. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
30. Epidermal growth factor receptor family and chemosensitization
31. ZD1839 ("Iressa") as an anti-cancer agent
32. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex)
33. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
34. Iressa augments Herceptin-induced apoptosis in breast cancer cells
35. Iressa targets HER-2 over expressing tumors that co-express HER1
36. AstraZeneca completes patient enrollment in NSCLC phase III trials of Iressa
37. Phase I study of oral ZD1839 (Iressa™), a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK): Evidence of good tolerability and activity
38. Final results of a phase I intermittent dose-escalation trial of ZD 1839 (Iressa) in Japanese patients with various solid tumours
39. The EGFR-selective tyrosine kinase inhibitor ZD1839 (Iressa) is an effective inhibitor of tamoxifen-resistant breast cancer growth
40. Feasibility and pharmacokinetic (PK) trial of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced colorectal cancer
41. A pilot trial demonstrates the safety of ZD1839 (Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC)
42. Objective regression in non-small cell lung cancer patients treated in phase I trials of ZD1839 (Iressa), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)